BR112022003935A2 - Rebamipida para uso em profilaxia e tratamento de doença celíaca - Google Patents

Rebamipida para uso em profilaxia e tratamento de doença celíaca

Info

Publication number
BR112022003935A2
BR112022003935A2 BR112022003935A BR112022003935A BR112022003935A2 BR 112022003935 A2 BR112022003935 A2 BR 112022003935A2 BR 112022003935 A BR112022003935 A BR 112022003935A BR 112022003935 A BR112022003935 A BR 112022003935A BR 112022003935 A2 BR112022003935 A2 BR 112022003935A2
Authority
BR
Brazil
Prior art keywords
rebamipide
celiac disease
prophylaxis
treatment
intestinal permeability
Prior art date
Application number
BR112022003935A
Other languages
English (en)
Inventor
6° § 4° Da Lpi 9279/96 Art
Original Assignee
Square Power Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Square Power Ltd filed Critical Square Power Ltd
Publication of BR112022003935A2 publication Critical patent/BR112022003935A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção fornece rebamipida para uso em um método de prevenção e/ou tratamento de doença celíaca, particularmente em uma pessoa que sofre de permeabilidade intestinal aumentada ou em uma pessoa em risco de permeabilidade intestinal aumentada. além disso, a presente invenção fornece rebamipida para uso em um método de inibição de um aumento induzido por glúten em permeabilidade intestinal.
BR112022003935A 2019-09-03 2020-09-02 Rebamipida para uso em profilaxia e tratamento de doença celíaca BR112022003935A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19020503.9A EP3797771B1 (en) 2019-09-03 2019-09-03 Rebamipide for use in prophylaxis and treatment of celiac disease
PCT/EP2020/074485 WO2021043835A1 (en) 2019-09-03 2020-09-02 Rebamipide for use in prophylaxis and treatment of celiac disease

Publications (1)

Publication Number Publication Date
BR112022003935A2 true BR112022003935A2 (pt) 2022-05-31

Family

ID=67874202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003935A BR112022003935A2 (pt) 2019-09-03 2020-09-02 Rebamipida para uso em profilaxia e tratamento de doença celíaca

Country Status (11)

Country Link
US (1) US20220304996A1 (pt)
EP (1) EP3797771B1 (pt)
JP (1) JP2022546120A (pt)
KR (1) KR20220062548A (pt)
CN (1) CN114340630B (pt)
BR (1) BR112022003935A2 (pt)
CA (1) CA3153325A1 (pt)
ES (1) ES2913792T3 (pt)
MX (1) MX2022002625A (pt)
PL (1) PL3797771T3 (pt)
WO (1) WO2021043835A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444823B (zh) * 2022-10-12 2024-02-23 苏州中化药品工业有限公司 一种含瑞巴派特颗粒及其制备方法和应用
KR20240111158A (ko) * 2023-01-09 2024-07-16 주식회사 포스테라헬스사이언스 레바미피드 또는 이의 약학적으로 허용 가능한 염을 유효 성분으로 포함하는 서방성 다층정제 및 이의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072113A2 (en) * 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
CN105943534A (zh) * 2008-04-15 2016-09-21 萨可德生物科学公司 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂
AR085527A1 (es) * 2011-03-24 2013-10-09 Otsuka Pharma Co Ltd Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
EP3125870A4 (en) * 2014-04-04 2017-12-13 Alba Therapeutics Corporation Methods of treating celiac disease with larazotide
PE20181295A1 (es) * 2015-09-01 2018-08-07 First Wave Bio Inc Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala

Also Published As

Publication number Publication date
JP2022546120A (ja) 2022-11-02
ES2913792T3 (es) 2022-06-06
EP3797771A1 (en) 2021-03-31
PL3797771T3 (pl) 2022-06-27
WO2021043835A1 (en) 2021-03-11
US20220304996A1 (en) 2022-09-29
CN114340630B (zh) 2024-05-14
CA3153325A1 (en) 2021-03-11
EP3797771B1 (en) 2022-02-23
CN114340630A (zh) 2022-04-12
KR20220062548A (ko) 2022-05-17
MX2022002625A (es) 2022-06-02

Similar Documents

Publication Publication Date Title
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
BR112017008093A2 (pt) processos para tratamento de doenças oculares
BR112018014222A2 (pt) método de tratamento da glomerulopatia c3
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
BR112018075135A2 (pt) combinações farmacêuticas para tratar câncer
BR112022003935A2 (pt) Rebamipida para uso em profilaxia e tratamento de doença celíaca
MX2022000441A (es) Metodos para tratar o prevenir la atrofia muscular espinal.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112018014762A2 (pt) método de tratamento da doença de alzheimer (da) precoce
MX2020012475A (es) Metodo para tratar el trastorno depresivo mayor.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
BR112019008241A2 (pt) tratamento do prurigo nodular
PH12017550047A1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
ZA202110052B (en) Rebamipide for use in prevention and / or treatment of synucleinopathies
MX2018013507A (es) Composiciones y metodos para el tratamiento de la inflamacion o infeccion del ojo.
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
EP3429567A4 (en) METHOD AND COMPOSITIONS FOR TREATING OBESITY AND / OR DIABETES AND IDENTIFYING TREATMENT CANDIDATES
BR112022003918A2 (pt) Rebamipida para uso na prevenção e tratamento da doença de crohn
BR112021017635A2 (pt) Composições e métodos para tratar a doença de huntington
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
MX2022006751A (es) Minitrampas de vegf y metodos de uso de las mismas.